MAL
MCID: MLR020
MIFTS: 28

Malaria, Mild (MAL)

Categories: Genetic diseases

Aliases & Classifications for Malaria, Mild

Summaries for Malaria, Mild

MalaCards based summary : Malaria, Mild, also known as malaria, mild, susceptibility to, is related to mal de meleda and mal de debarquement syndrome. An important gene associated with Malaria, Mild is NCR3 (Natural Cytotoxicity Triggering Receptor 3). The drugs Aminolevulinic acid and Prilocaine have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and neutrophil.

More information from OMIM: 609148

Related Diseases for Malaria, Mild

Diseases related to Malaria, Mild via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 mal de meleda 11.7
2 mal de debarquement syndrome 11.6
3 median arcuate ligament syndrome 11.4
4 epilepsy, myoclonic juvenile 11.4
5 childhood absence epilepsy 11.3
6 status epilepticus 11.2
7 pinta disease 11.2
8 naxos disease 11.2
9 metachromatic leukodystrophy 11.1
10 cervix uteri carcinoma in situ 11.0
11 neurodegeneration with brain iron accumulation 5 11.0
12 chromosome 15q11-q13 duplication syndrome 11.0
13 salt and pepper developmental regression syndrome 11.0
14 palmoplantar keratoderma, nagashima type 11.0
15 epilepsy with generalized tonic-clonic seizures 10.9
16 noonan syndrome 3 10.9
17 uterus carcinoma in situ 10.9
18 epilepsy, idiopathic generalized 10.9
19 spinal muscular atrophy with progressive myoclonic epilepsy 10.8
20 deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures syndrome 10.8
21 papillon-lefevre syndrome 10.8
22 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.8
23 argentine hemorrhagic fever 10.8
24 juvenile absence epilepsy 10.8
25 benign neonatal seizures 10.8
26 unverricht-lundborg syndrome 10.8
27 prickle1-related progressive myoclonus epilepsy with ataxia 10.8
28 progressive myoclonus epilepsy, lafora type 10.8
29 seizure disorder 10.8
30 palmoplantar keratosis 10.5
31 keratosis 10.4
32 epilepsy 10.4
33 rare epilepsy 10.2
34 early myoclonic encephalopathy 10.2
35 actinic keratosis 10.2
36 migraine with or without aura 1 10.2
37 cervical intraepithelial neoplasia 10.2
38 apple allergy 10.2
39 myoclonus 10.2
40 skin disease 10.1
41 b-cell lymphoma 10.1
42 esophageal cancer 10.1
43 motion sickness 10.1
44 dermatitis, atopic 10.1
45 food allergy 10.1
46 cervical cancer 10.1
47 primary mediastinal large b-cell lymphoma 10.1
48 malaria 10.0
49 acute leukemia 10.0
50 melanoma 10.0

Graphical network of the top 20 diseases related to Malaria, Mild:



Diseases related to Malaria, Mild

Symptoms & Phenotypes for Malaria, Mild

Clinical features from OMIM®:

609148 (Updated 05-Apr-2021)

Drugs & Therapeutics for Malaria, Mild

Drugs for Malaria, Mild (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4 106-60-5 137
2
Prilocaine Approved Phase 4 721-50-6 4906
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Ethanol Approved Phase 4 64-17-5 702
5
Protoporphyrin IX Experimental Phase 4 553-12-8
6 Methyl 5-aminolevulinate Phase 4
7 Photosensitizing Agents Phase 4
8 Dermatologic Agents Phase 4
9 Sunscreening Agents Phase 4
10 Anesthetics Phase 4
11 Anti-Arrhythmia Agents Phase 4
12 Sodium Channel Blockers Phase 4
13 Diuretics, Potassium Sparing Phase 4
14 Anesthetics, Local Phase 4
15 Lidocaine, Prilocaine Drug Combination Phase 4
16
Phenytoin Approved, Vet_approved Phase 3 57-41-0 1775
17
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
18 Psychotropic Drugs Phase 3
19 Neurotransmitter Agents Phase 3
20 Anticonvulsants Phase 3
21
Levetiracetam Approved Phase 2 102767-28-2 441341
22
Fluoxymesterone Approved, Illicit Phase 1, Phase 2 76-43-7 6446
23 Nootropic Agents Phase 2
24 Pharmaceutical Solutions Phase 1, Phase 2
25
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
26
Magnesium hydroxide Approved, Investigational Phase 1 1309-42-8
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
28 Vitamins Phase 1
29 Calciferol Phase 1
30 Calcipotriene Phase 1
31 Nutrients Phase 1
32 Micronutrients Phase 1
33 Trace Elements Phase 1
34 Gastrointestinal Agents Phase 1
35 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 1
36 Integrase Inhibitors Phase 1
37 Raltegravir Potassium Phase 1
38 Anti-Retroviral Agents Phase 1
39 HIV Integrase Inhibitors Phase 1
40 Anti-Ulcer Agents Phase 1
41 Antiviral Agents Phase 1
42 Anti-HIV Agents Phase 1
43 Antacids Phase 1
44 Anti-Infective Agents Phase 1
45
Caffeine Approved 58-08-2 2519
46
Exenatide Approved, Investigational Early Phase 1 141758-74-9 15991534
47
Triamcinolone Approved, Vet_approved 124-94-7 31307
48
Cysteine Approved, Nutraceutical Early Phase 1 52-90-4 5862
49 Incretins Early Phase 1
50 Hormone Antagonists Early Phase 1

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
2 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Completed NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
3 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
4 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
5 Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility Completed NCT01586208 Phase 3 valproic acid (VPA)
6 A Double-blind, Multicenter, Long-term Follow-up Study to Assess Recurrence of Actinic Keratosis in Subjects Treated With Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) or Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT), for Subjects Achieving Complete Response of Treated Lesions at Final Visit in Study RD.06.SPR.112199 Recruiting NCT04269395 Phase 3 MAL Cream;Vehicle cream
7 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis (AK) of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT) Active, not recruiting NCT04085367 Phase 3 MAL 16.8% cream
8 Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis. Unknown status NCT02354391 Phase 2 Ingenol mebutate Picato® and MAL PDT day 1, day 5;Ingenol mebutate Picato® day 2, 3, 4
9 Pretreatment With Ablative Fractional Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin Completed NCT03006185 Phase 2
10 Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus : An Open Randomized Study Completed NCT02920060 Phase 2 Intravenous levetiracetam;Sodium valproate
11 Methyl Aminolevulinate (MAL) and Hexaminolevulinate (HAL) Photodynamic Therapy (PDT)of Cervical Intraepithelial Lesions (SIL) - a Double-blind Dose-finding Study Completed NCT00369018 Phase 1, Phase 2 methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
12 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne Completed NCT00594425 Phase 2 Methyl aminolevulinate (MAL) PDT
13 A Blinded, Randomized, Intra-individual, Vehicle-controlled and Multi-centre Study of Photodynamic Therapy With MAL Cream in Patients With Skin Type V or VI With Acne Vulgaris Completed NCT00673933 Phase 2 Methyl aminolevulinate (MAL) PDT
14 Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate Completed NCT02149342 Phase 1, Phase 2 Hexylaminolaevulinate cream;Methylaminolaevulinate cream
15 Pretreatments of the Skin to Enhance MAL-induced Protoporphyrin IX (PpIX) Accumulation Prior to Photodynamic Therapy (PDT) Completed NCT02372370 Phase 1 MAL Control.
16 Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy With Short Incubation Time for the Treatment of Facial and Scalp Actinic Keratosis: 12-month Follow-up Results of a Randomized, Prospective, Comparative Trial Completed NCT02248298 Phase 1 2h-AFL-PDT;3h-AFL-PDT;3hr-MAL-PDT
17 A Randomized, Intra-individual, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment in Asian Patients With Lower Extremity Bowen's Disease Completed NCT01912976 Phase 1 Er:YAG AFL-PDT;MAL-PDT
18 Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Nodular Basal Cell Carcinoma in Asian: A Prospective, Randomized Study With 12 Months Follow-up Completed NCT02018679 Phase 1
19 A Randomized, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment for Actinic Cheilitis Completed NCT02198469 Phase 1 Er:YAG AFL-PDT;MAL-PDT
20 Efficacy of Topical Calcipotriol-assisted Ablative Fractional Laser Photodynamic Therapy for the Treatment of Actinic Keratosis: 12-month Follow-up Results of a Prospective, Randomised, Comparative Trial Completed NCT02976727 Phase 1 Topical Vitamin D (Calcipotriol) application;Placebo cream application;lidocaine/prilocaine (5%) application;MAL application
21 Efficacy of Iontophoresis-assisted Ablative Fractional Laser Photodynamic Therapy With Short Incubation Time for the Treatment of Actinic Keratosis: 12-month Follow-up Results of a Prospective, Randomised, Comparative Trial Completed NCT02670655 Phase 1 lidocaine/prilocaine (5%) application;MAL application
22 Efficacy in Ablative Fractional Laser Assisted Photodynamic Therapy According to Ablative Depth for Actinic Keratosis Completed NCT03325803 Phase 1 lidocaine/prilocaine (5%) application;MAL application
23 A Phase I Study for Superficial Basal Cell Carcinoma to Determine the Irradiance - Dependent Pain Threshold for Methylaminolevulinate (MAL)/PDT. Completed NCT01292668 Phase 1 methyl-5-aminolevulinate hydrochloride cream;photodynamic therapy
24 A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen Completed NCT01930045 Phase 1 Raltegravir (ISENTRESS™);MAALOX (MAL)
25 Long-term Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy for Treatment of Lower Extremity Bowen's Disease: A Prospective, Randomized, Controlled Trial With 5-year Follow up Completed NCT03320447 Phase 1 lidocaine-prilocaine 5% cream application;methyl-aminolevulinate application
26 A Randomised Trial Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: Results From a 24-month Follow-up Completed NCT02666534 Phase 1 lidocaine-prilocaine 5% cream application;methyl-aminolevulinate application
27 Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study) Unknown status NCT01080690
28 Effects of Constraint-induced Therapy for the Scapular Kinematics and Related to the Quality of Movement in Patients With Severe Chronic Hemiparesis Unknown status NCT02373436
29 Transepidermal Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin Completed NCT03963765
30 Efficacy of Calcipotriol Assisted MAL-PDT Versus Conventional MAL-PDT for Actinic Keratosis: a Randomized and Controlled Study Completed NCT02878382
31 Somatic-psychosocial Multidisciplinary Care Concept for Oncologic Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): a Prospective Non-randomized Clinical Trial Completed NCT00804817
32 Comparison of a Novel Weight Bearing Cone Beam Computed Tomography (CT)Scanner Versus a Conventional CT Scanner for Measuring Patellar Instability Completed NCT02257099
33 Histological and Immunohistochemical Study of Photodamaged Skin Submitted to MAL-PDT Completed NCT00843323
34 Preliminary Study to Evaluate the Effect of an EEG-proprioceptive Neurofeedback on Cortical Excitability and Motor Function of the Upper Limb After Stroke Recruiting NCT04130711
35 Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma Recruiting NCT04185350 Early Phase 1 68Ga-NOTA-MAL-Cys39-exendin-4
36 A Phase II, Single-center STudy on the vAlue of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET)InformatiOn IN Subtype of Metastatic Breast Cancer(MBC) Recruiting NCT04758416 68Ga-HER2 affibody,18F-FDG, 18F-FES
37 Gait Training Combined With Strategies to Induce Transference to Real Life for People With Stroke Recruiting NCT04546217
38 Transcranial Electrical Stimulation for Mal de Debarquement Syndrome Active, not recruiting NCT02540616
39 Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome Active, not recruiting NCT02470377
40 Treatments of Mal de Debarquement Syndrome (MdDS) by Habituation of Velocity Storage Active, not recruiting NCT04213079
41 Translation and Transcultural Adaptation of the Arm Activity Measure (ArmA) and Motor Activity Log (MAL) to Assess Perceived Performance of the Upper Limb Use in Adults With Subacute and Chronic Stroke. F-ArmA Active, not recruiting NCT04754555
42 Dynamic 4DCT to Examine the Effect of Mal-united Distal Radius Fractures on Carpal Contact Mechanics Active, not recruiting NCT04402502
43 Effect of Moderate Weight Loss in Metabolically Abnormal Lean Subjects Active, not recruiting NCT02452567
44 WAVES: Wobble-oscillator Auditory/Visual Excitatory Stimulation for Mal de Debarquement Syndrome Not yet recruiting NCT04612010 Early Phase 1
45 Compassionate Use of Metvix® (Methyl Aminolevulinate) PDT in Subjects With Field Actinic Keratoses, Large/Multiple Superficial BCCs, or Bowen's Disease No longer available NCT00535080 Metvix (methyl aminolevulinate)
46 Transdiagnostic Interventions for Emotional Disorders Suspended NCT03855683
47 A Phase II Study Evaluating the Non-inferiority of the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy (PDT) Terminated NCT03076918

Search NIH Clinical Center for Malaria, Mild

Genetic Tests for Malaria, Mild

Genetic tests related to Malaria, Mild:

# Genetic test Affiliating Genes
1 Malaria, Mild, Susceptibility to 29 NCR3

Anatomical Context for Malaria, Mild

MalaCards organs/tissues related to Malaria, Mild:

40
Skin, Liver, Neutrophil

Publications for Malaria, Mild

Articles related to Malaria, Mild:

(show all 13)
# Title Authors PMID Year
1
Association analyses of NCR3 polymorphisms with P. falciparum mild malaria. 57 6
17208487 2007
2
Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso. 57
12566384 2003
3
Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. 57
9240049 1997
4
Cook's Endeavour, ship of discovery or ship of distemper: an assessment after 250 years. 61
32270624 2020
5
MBL2 variations and malaria susceptibility in Indian populations. 61
24126531 2014
6
Elevated plasma von Willebrand factor and propeptide levels in Malawian children with malaria. 61
22125593 2011
7
Knowledge and practices for preventing severe malaria in Yemen: the importance of gender in planning policy. 61
19726561 2009
8
Family-based association of a low producing lymphotoxin-alpha allele with reduced Plasmodium falciparum parasitemia. 61
18457972 2008
9
Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study. 61
16652286 2006
10
Human neutrophil lipocalin: a specific marker for neutrophil activation in severe Plasmodium falciparum malaria. 61
12826303 2003
11
Intraleucocytic malaria pigment and clinical severity of malaria in children. 61
9692152 1998
12
Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria. 61
7927698 1994
13
Tumor necrosis factor and severe malaria. 61
1984482 1991

Variations for Malaria, Mild

ClinVar genetic disease variations for Malaria, Mild:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NCR3 NM_001145466.1(NCR3):c.-412G>C SNV risk factor 876 rs2736191 GRCh37: 6:31560910-31560910
GRCh38: 6:31593133-31593133

Expression for Malaria, Mild

Search GEO for disease gene expression data for Malaria, Mild.

Pathways for Malaria, Mild

GO Terms for Malaria, Mild

Sources for Malaria, Mild

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....